Atuka provides contract research and consultancy services for the biopharmaceutical industry with world-leading expertise in Parkinson’s disease and related neurological conditions. We provide cutting-edge, rodent and non-human primate models (toxin and molecular pathology-driven) to evaluate efficacy and target engagement over a comprehensive range of symptomatic, motor (e.g. parkinsonism and dyskinesia), non-motor (e.g. cognition and impulse control) and disease-modification assays. Atuka also offers medicinal chemistry, DMPK and in-vivo imaging services to aid development of novel therapeutics.
The Jackson Laboratory (JAX) is an independent, nonprofit biomedical research institute combining innovation, reliability, and commitment to customer service to provide the most clinically relevant mouse models and precision services. With an extensive and ever expanding portfolio of mouse models and services such as target validation and drug efficacy studies, JAX is committed to providing researchers with the most advanced tools
to support their neurobiological research and enable efficacious drug design.
Certara is the global leader in advancing modern, efficient drug development. We provide proven modeling & simulation, regulatory and real world value assessment software and services. In partnership with our clients, we help reduce clinical trial burden, accelerate regulatory approval and increase patient access to medicines. 90% of all novel drugs approved by FDA have used Certara software and/or services.
QurAlis is bringing hope to the ALS community by developing breakthrough precision medicines for this devastating disease. Our stem cell technologies generate proprietary human neuronal models that enable us to more effectively discover and develop innovative therapies for genetically validated targets. We are advancing three therapeutic programs addressing sub-forms of ALS that account for the majority of patients. With our world-class network of thought leaders, drug developers and patient advocates, our team is rising to the challenge of conquering ALS.
bit.bio is an award-winning human synthetic biology enterprise. Our mission is to code cells for health. Our current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: enabling research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease.
Proprietary MultiBrain® technology powers NSA’s simultaneous sectioning, and expertly-guided staining, of up to 40 neuronal tissues in one MultiBrain® block, achieving uniform processing across all 40 tissues. Implementing NSA’s Large Format™ technology enables sectioning and staining of intact human brain hemispheres and yields comprehensive, uninterrupted vantage and analysis of the ultimate target. Coupling these mass production technologies with cutting-edge digital image capture and hosting, along with contemporary analysis tools increasingly powered by AI, rapidly produces rich data, and dramatically reduces R&D times.
Genuity Science is a data sourcing, analytics, and insights organization headquartered in Boston, Massachusetts, USA, with offices in Dublin, Ireland, and Reykjavik, Iceland. Genuity Science partners with global biopharma companies to offer deep end-to-end discovery services aimed at catalyzing precision health and improving the quality of life for patients around the world. Services include population-scale, disease-specific data sourcing, high-quality sequencing, robust statistical analysis, and software tools for analyzing large datasets and artificial intelligence (AI). The company operates advanced CAP-accredited, CLIA-certified genomics laboratories in Woburn, Massachusetts, USA, and in Dublin, Ireland, and is deeply committed to data stewardship and data governance across its global offices. For more information, see www.genuitysci.com
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 25,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.
Genomenon is a genomic health IT company that keeps pace with the constant advancements made in genomics and connects that research to patient DNA to help diagnose and treat patients with rare genetic diseases and cancer. Mastermind Genomic Landscapes inform pharmaceutical companies on precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence. Genomenon was named Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan
Cellectricon is a leading provider of neurobiology in vitro research services. Our mission is to create groundbreaking in vitro concepts that will advance the neuroscience research field and enable our Clients to conduct successful drug discovery programs. We are a team of highly experienced neurobiologists, stem cell researchers and engineers with a proven track record of delivering successful projects to our Clients. We always aim for long-term partnerships with our Clients, based on mutual trust and commitment.
Lipotype is the leading lipidomics service provider for every researcher. Our mass spectrometry-based technology identifies more than 3100 individual lipids in minutes and covers a rich variety of sample types while requiring only minimal sample amounts. Lipotype Shotgun Lipidomics empowers scientists from academia to industry to reach their research goals through comparable, quantitative lipidomics data. Contact us, order your lipidomics services, send in your samples, and study your reports in as little as two weeks.
Founded in 2008, we are a privately-held biotech company and we work with big pharma, biotech and academia across the world. Through a constant focus on high quality, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.
To study pre-clinical models of neurodegeneration we have developed an innovative pipeline for quantitative whole brain imaging. By combining light sheet microscopy, AI powered image analysis and cloud-based data reporting it is possible to count single cells, plaques or quantify drug distribution. To try it out click on the Gubra 3D experience below.